RxDoctor Payments Data

Jianping Zhang, MD

Psychiatry · Glen Oaks, NYNPI 1528233293

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 6 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. E.r. Squibb & Sons, L.L.C. accounts for 93.4% of it on its own, with 1 other manufacturer making up the rest.

$200in general payments, 2019–2025

Across 6 payments — averaging $33.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$187
  • AbbVie$13
$221,338in research payments, 2019–2025

Across 27 payments — averaging $8197.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Janssen Research & Development, LLC$221K

What the payments were for

  • Food & beverage$200100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
E.r. Squibb & Sons, L.L.C.5$187
AbbVie1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$200 in reported general payments places this provider in the 55th percentile of 3,713 psychiatry providers in New York.

See all psychiatry providers in New York →

Medicare billing

Part B allowed, 2024
$19,949
Medicare patients
20
Services billed
180

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole24$35,248
Mirtazapine992$11,083
Ramelteon63$5,829
TrintellixVortioxetine Hydrobromide12$4,930
Clonazepam532$2,670
Quetiapine Fumarate260$2,544
Duloxetine Hcl208$2,200
Zolpidem Tartrate264$1,896
Olanzapine124$1,567
Escitalopram Oxalate318$1,444
Bupropion XlBupropion Hcl112$1,369
Aripiprazole68$1,271
Methylphenidate Hcl20$1,255
Venlafaxine Hcl ErVenlafaxine Hcl104$1,053
Fluoxetine Hcl260$970

Paid to pharmacies, not to this prescriber.

Other psychiatry in Glen Oaks

See the full list for New York →

Where these figures come from

Is this you, or does something look wrong? →